An Evaluation of Immunogenicity and Safety of Two Doses of MVA-nef vs. MVA-BN in HIV-1 Infected Patients

NCT00189930 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

77

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infection

Interventions

BIOLOGICAL: MVA-nef
BIOLOGICAL: IMVAMUNE

Sponsor

Bavarian Nordic

Collaborators

[object Object]